FDA Reattempts Guidance On Third-Party 510(k) Review Program
Executive Summary
FDA is again attempting to outline its thinking on the 510(k) third-party review program in a new draft guidance. The program, which allows accredited organizations to conduct 510(k) reviews for certain products, has had a lackluster performance since it was first mandated by Congress in 1997.
You may also be interested in...
Senate, House Panels Release Clean Device User-Fee Discussion Draft
Lawmakers emphasized the need for a swift reauthorization of a combined US FDA device and drug user-fee reauthorization bill before the end of July, and released a clean discussion draft April 14 that mirrors the agreements reached by industry and the agency last summer.
Must-Do Guidance Development: What's On Tap From Cures, MDUFA IV
US FDA's device center is facing new mandates and commitments to develop guidelines for industry. The guidance-development stipulations in the 21st Century Cures Act and the recent MDUFA IV user-fee agreement are detailed below.
Global Regulatory Guidelines: Medtech Guidance Tracker, Sept.-Oct. 2016
Stay up-to-date on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. In the latest update, documents posted in September and October 2016.